Clinical Study of Nasopharyngeal Carcinoma Treated by Helical Tomotherapy in China: 5-Year Outcomes

Table 6

Log-rank test for univariate analysis.

Factor	3-year LRFS			3-year NRFS			3-year DMFS			3-year OS
Age (y)
≤50	94.8%	𝜒^2=4.046	𝐏=𝟎.𝟎𝟒𝟒	94.8%	𝜒^2=1.211	𝑃=0.271	91.5%	𝜒^2=6.063	𝐏=𝟎.𝟎𝟏𝟒	83.1%	𝜒^2=6.791	𝐏=𝟎.𝟎𝟎𝟗
>50	80.8%			100.0%			70.4%			58.8%
Gender
Male	93.7%	𝜒^2=2.848	𝑃=0.091	96.8%	𝜒^2=0.202	𝑃=0.653	82.1%	𝜒^2=1.815	𝑃=0.178	74.0%	𝜒^2=0.135	𝑃=0.713
Female	81.0%			94.4%			94.7%			77.3%
T Stage
T1	88.9%	𝜒^2=7.424	𝑃=0.060	100.0%	𝜒^2=11.293	𝐏=𝟎.𝟎𝟏𝟎	89.5%	𝜒^2=1.357	𝑃=0.716	81.0%	𝜒^2=10.218	𝐏=𝟎.𝟎𝟏𝟕
T2	97.7%			100.0%			87.0%			85.1%
T3	80.0%			80.0%			77.8%			53.8%
T4	70.5%			90.9%			75.0%			55.6%
N Stage
N0	85.7%	𝜒^2=1287	𝑃=0.732	100.0%	𝜒^2=6.116	𝑃=0.160	100.0%	𝜒^2=8.160	𝐏=𝟎.𝟎𝟒𝟑	85.7%	𝜒^2=1.765	𝑃=0.622
N1	90.0%			100.0%			72.7%			70.3%
N2	92.6%			92.9%			86.2%			73.5%
N3	100.0%			83.3%			100.0%			71.4%
Node category
N+	85.7%	𝜒^2=0.722	𝑃=0.395	100.0%	𝜒^2=0.871	𝑃=0.351	100.0%	𝜒^2=3.782	𝑃=0.052	85.7%	𝜒^2=1.700	𝑃=0.192
N−	92.1%			95.2%			80.9%			71.8%
UICC Stage
I	83.3%	𝜒^2=6.097	𝑃=0.107	100.0%	𝜒^2=3.235	𝑃=0.357	100.0%	𝜒^2=1.634	𝑃=0.652	82.5%	𝜒^2=3.645	𝑃=0.302
II	100.0%			100.0%			82.1%			85.0%
III	86.7%			93.1%			83.3%			96.4%
IV	80.0%			90.9%			91.7%			66.7%
IGRT and GTVnx to pGTVnx margin
Every day and 5 mm	92.5%	𝜒^2=1.098	𝑃=0.295	100%	𝜒^2=1.096	𝑃=0.295	86.8%	𝜒^2=1.409	𝑃=0.306	81.1%	𝜒^2=0.299	𝑃=0.585
Every week and 3 mm	96.8%			97.9%			93.7%			86.3%
Chemotherapy was performed or not in stage III-IV patients
No	57.1%	𝜒^2=4.563	𝐏=𝟎.𝟎𝟑𝟑	100.0%	𝜒^2=0.406	𝑃=0.524	57.1%	𝜒^2=4.563	𝐏=𝟎.𝟎𝟑𝟑	55.6%	𝜒^2=0.648	𝑃=0.421
Yes	90.0%			92.1%			90.0%			71.7%
Concurrent chemotherapy was performed or not in stage III-IV patients
No	81.5%	𝜒^2=0.577	𝑃=0.447	91.7%	𝜒^2=0.150	𝑃=0.699	81.5%	𝜒^2=0.577	𝑃=0.447	70.0%	𝜒^2=0.047	𝑃=0.829
Yes	90.0%			94.7%			90.0%			68.0%
Anti-EGFR monoclonal antibody was used or not in stage III-IV patients
No	84.0%	𝜒^2=0.071	𝑃=0.789	91.3%	𝜒^2=0.219	𝑃=0.640	84.0%	𝜒^2=0.071	𝑃=0.789	65.6%	𝜒^2=0.399	𝑃=0.528
Yes	86.4%			95.0%			86.4%			73.9%